These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24862945)

  • 1. Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.
    Tfelt-Hansen PC; Diener HC
    Headache; 2014 Oct; 54(9):1523-5. PubMed ID: 24862945
    [No Abstract]   [Full Text] [Related]  

  • 2. Ergotamine, dihydroergotamine: current uses and problems.
    Tfelt-Hansen P
    Curr Med Res Opin; 2001; 17 Suppl 1():s30-4. PubMed ID: 12463275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE).
    Rothrock JF
    Headache; 2007 May; 47(5):740. PubMed ID: 17501862
    [No Abstract]   [Full Text] [Related]  

  • 4. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transformed migraine--chronic daily headache].
    Bøe MG; Monstad P
    Tidsskr Nor Laegeforen; 1999 Nov; 119(29):4311-3. PubMed ID: 10667127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
    Swidan SZ; Lake AE; Saper JR
    Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
    Aurora SK; Silberstein SD; Kori SH; Tepper SJ; Borland SW; Wang M; Dodick DW
    Headache; 2011 Apr; 51(4):507-17. PubMed ID: 21457235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
    Chou DE; Tso AR; Goadsby PJ
    Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.
    Bekan G; Tfelt-Hansen P
    Headache; 2016 Oct; 56(9):1482-1491. PubMed ID: 27595607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exacerbation of SUNCT and SUNA syndromes during intravenous dihydroergotamine treatment: A case series.
    Lambru G; Shanahan P; Matharu M
    Cephalalgia; 2015 Oct; 35(12):1115-24. PubMed ID: 25667300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DHE in the pharmacotherapy of migraine: potential for a larger role.
    Saper JR; Silberstein S; Dodick D; Rapoport A
    Headache; 2006 Nov; 46 Suppl 4():S212-20. PubMed ID: 17078853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroergotamine suppositories in a headache clinic.
    Ward TN; Scott G
    Headache; 1991 Jul; 31(7):465-6. PubMed ID: 1774163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.